Evidence map›Paper›PMID 24949113›Full record

ReviewThe EPMA journal2014

Personalized approach to primary and secondary prevention of ischemic stroke.

Jiří Polívka, Vladimír Rohan, Petr Sevčík, Jiří Polívka

Abstract readReview
In one paragraph

Review in The EPMA journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Strokes in young adults: epidemiology and prevention.Vascular health and risk management · 2015
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jiří PolívkaDepartment of Neurology, Faculty of Medicine in Pilsen, Charles University in Prague, Alej Svodody 80, Pilsen 304 60, Czech Republic ; Department of Neurology, University Hospital Pilsen, Alej Svodody 80, Pilsen 304 60, Czech Republic.
Vladimír RohanDepartment of Neurology, Faculty of Medicine in Pilsen, Charles University in Prague, Alej Svodody 80, Pilsen 304 60, Czech Republic ; Department of Neurology, University Hospital Pilsen, Alej Svodody 80, Pilsen 304 60, Czech Republic.
Petr SevčíkDepartment of Neurology, Faculty of Medicine in Pilsen, Charles University in Prague, Alej Svodody 80, Pilsen 304 60, Czech Republic ; Department of Neurology, University Hospital Pilsen, Alej Svodody 80, Pilsen 304 60, Czech Republic.
Jiří PolívkaDepartment of Histology and Embryology, Faculty of Medicine in Pilsen, Charles University in Prague, Karlovarska 48, Pilsen 301 66, Czech Republic ; Biomedical Centre, Faculty of Medicine in Pilsen, Charles University in Prague, Karlovarska 48, Pilsen 301 66, Czech Republic.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary and secondary prevention of ischemic stroke represents a significant part of stroke management and health care. Although there are official guidelines concerning stroke management, new knowledge are introduced to them with a slight delay. This article provides an overview of current information on primary and secondary prevention of ischemic stroke. It summarizes information especially in the field of cardioembolic stroke, the use of new anticoagulants and the management of carotid stenosis based on the results of recent clinical studies. The optimal approach in stroke management is to follow these recommendations, to know new strategies and to apply an individual personalized approach in our clinical decisions.

Indexed as

Anticoagulation therapyAntiplatelet therapyIschemic strokePersonalized medicinePrimary preventionSecondary prevention

Identifiers

PMID24949113
PMCPMC4063244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.